Inflammatory Arthritis Treatment Denied by Insurance? How to Appeal

Inflammatory arthritis encompasses a family of conditions — including psoriatic arthritis (PsA), ankylosing spondylitis (AS, now classified as axial spondyloarthritis/axSpA), and reactive arthritis — that cause progressive joint damage, disability, and systemic inflammation. Biologic therapies (TNF inhibitors, IL-17 inhibitors, JAK inhibitors) have transformed treatment outcomes, but insurance denials are extremely common. This guide covers the key denial patterns and how to build an effective appeal.

Why Insurers Deny Inflammatory Arthritis Treatment

Step therapy — NSAID/DMARD failure required — For ankylosing spondylitis and axial spondyloarthritis, insurers typically require documented failure of two NSAIDs (at full anti-inflammatory doses for at least 4 weeks each) before approving a biologic. For psoriatic arthritis, many plans require failure of a conventional DMARD (methotrexate, sulfasalazine, or leflunomide) before approving biologics, despite the fact that PsA responds poorly to conventional DMARDs compared to RA.

Wrong biologic selected — Your plan may cover some biologics but not others for your specific diagnosis. For axSpA, IL-12/23 inhibitors (ustekinumab/Stelara) are not effective and not FDA-approved, while IL-17 inhibitors (secukinumab/Cosentyx, ixekizumab/Taltz) and TNF inhibitors (adalimumab, etanercept, certolizumab, infliximab, golimumab) are. Make sure your appeal is for an FDA-approved biologic for your specific diagnosis.

Diagnosis not confirmed — Insurers may question whether your diagnosis meets criteria for PsA, AS, or axSpA. Documentation of inflammatory back pain characteristics, sacroiliitis on MRI or X-ray, HLA-B27 positivity, or skin/nail psoriasis involvement (for PsA) may be required.

Active disease not documented — Insurers often require evidence of active disease despite treatment. For axSpA, BASDAI >4 or ASDAS-CRP ≥2.1 documents active disease. For PsA, joint counts, DAPSA, or MDA criteria are used.

Insurance preferred biologic substituted — Plans may approve a cheaper TNF inhibitor biosimilar instead of the IL-17 inhibitor your rheumatologist recommends, despite different mechanisms and different response profiles.

Clinical Frameworks Supporting Your Appeal

ACR Axial Spondyloarthritis Guideline (2019) — The ACR strongly recommends TNF inhibitors and IL-17 inhibitors for active axSpA/AS patients who have failed NSAID therapy. The guideline explicitly states that conventional DMARDs (methotrexate, sulfasalazine) are NOT recommended for axial disease — only for peripheral joint and enthesitis manifestations. If your insurer is requiring methotrexate step therapy for axial AS, this directly contradicts ACR guidelines.

ASAS Classification Criteria — The Assessment of SpondyloArthritis international Society (ASAS) criteria classify patients with inflammatory back pain into radiographic axSpA (X-ray sacroiliitis) and non-radiographic axSpA (MRI sacroiliitis without X-ray changes). Non-radiographic axSpA patients are often denied biologic therapy because X-rays are normal. The ASAS criteria, ASDAS activity scoring, and MRI sacroiliitis documentation support biologic therapy for non-radiographic axSpA.

ACR Psoriatic Arthritis Guideline (2018, updated 2021) — For PsA, the ACR recommends TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors (for patients with skin predominance), and JAK inhibitors (upadacitinib) as appropriate first-line biologics for active PsA. The guideline does not require DMARD failure before biologic initiation in active PsA — this is an important distinction from RA. If your plan is requiring csDMARD step therapy for PsA, cite the ACR guideline directly.

MRI Sacroiliitis Documentation — For non-radiographic axSpA, MRI showing bone marrow edema in the sacroiliac joints (positive STIR sequences) confirms active sacroiliitis and is a key piece of evidence for biologic authorization. Include the MRI report with specific description of sacroiliac joint findings.

BASDAI and ASDAS Scores — Submit your BASDAI (Bath AS Disease Activity Index) score ≥4 or ASDAS-CRP ≥2.1, which document active AS/axSpA meeting criteria for biologic therapy. These validated indices are used in clinical trial eligibility criteria and are accepted by most insurers.

HLA-B27 — While not diagnostic alone, HLA-B27 positivity (present in 80–90% of AS patients vs. 8% of the general population) supports the diagnosis in the clinical context. Include your HLA-B27 result.

Step-by-Step Appeal Strategy

Step 1: Confirm your exact diagnosis and the FDA-approved indications for the requested biologic. For axSpA, confirm whether radiographic or non-radiographic — the FDA approvals differ slightly. For PsA, confirm active articular disease, skin involvement, and any axial symptoms. Submit the appropriate classification criteria documentation.

Step 2: Document NSAID trial for axSpA. List each NSAID tried (naproxen, diclofenac, celecoxib, indomethacin), dose, duration (at least 4 weeks each at full anti-inflammatory dose), and reason for discontinuation or inadequate response. Include notes documenting continued back pain and morning stiffness despite NSAID therapy.

Step 3: For PsA, argue against mandatory csDMARD step therapy. Cite ACR 2021 PsA guideline language that does not require csDMARD step therapy before biologics for most presentations of PsA. If your plan requires methotrexate first, note that methotrexate is not FDA-approved for PsA (though used off-label) and the ACR guideline does not mandate it.

Step 4: Submit disease activity scores. BASDAI, ASDAS, DAPSA (for PsA), or other validated scores document current disease activity. Include the specific numeric score and the interpretation (moderate/high active disease).

Step 5: Include imaging. X-ray evidence of sacroiliitis, spinal syndesmophytes, or peripheral joint erosions, and/or MRI bone marrow edema in the sacroiliac joints. Radiographic progression documents urgency.

Step 6: Submit a Letter of Medical Necessity from a rheumatologist. Rheumatologists familiar with spondyloarthritis write the most effective LMNs. The letter should address diagnosis criteria, disease activity, failed NSAID/DMARD therapy, and rationale for the specific biologic requested.

Reactive Arthritis: A Special Case

Reactive arthritis (previously Reiter syndrome) is often triggered by genitourinary or gastrointestinal infection and usually self-resolves, but chronic or recurrent cases may require DMARD or biologic therapy. Insurers frequently deny biologics for chronic reactive arthritis because it is not routinely included in biologic labeling. However, reactive arthritis that meets spondyloarthritis classification criteria may be treated under the axSpA indication.

Fight Back With ClaimBack

Inflammatory arthritis is progressive and destructive. Delays in biologic therapy allow structural damage that cannot be reversed. ClaimBack helps you compile your diagnostic criteria, disease activity scores, imaging, and ACR/ASAS guidelines into a targeted appeal.

Start your inflammatory arthritis appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeals